AI in Neuro-Oncology: An Overarching Review

Clicks: 33
ID: 332204
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #56 of 286 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 286 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Artificial intelligence (AI) is increasingly being applied across neuro-oncology domains to analyze complex, high-dimensional, multimodal data. Despite major advances in the biological understanding and classification of CNS tumors, clinical outcomes for many of them remain poor, reflecting intra- and inter-tumor heterogeneity and limitations of conventional reductionist approaches. AI offers a paradigm shift to capture this heterogeneity and provide quantitative, reproducible diagnostic, predictive, and prognostic insights. This article describes a joint effort across the Response Assessment in Neuro-Oncology (RANO) working groups to provide an overarching review of the AI use across six key domains of neuro-oncology: neuroimaging, neuropathology, laboratory medicine, neurosurgery, drug discovery, and clinical trials. Applications closest to clinical use include imaging segmentation and quantification, AI-assisted image reconstruction, DNA methylation-based classification, and workflow optimization. Radiogenomics, WSI-based molecular prediction, AI-guided surgical targeting, liquid biopsy interpretation, AI-guided drug discovery, digital twins, and in silico trials remain promising but require stronger prospective validation. Key challenges include limited availability of large diverse datasets, variability in data acquisition and reference standards, and limited external validation. This review provides a unifying framework for understanding the role of AI across neuro-oncology and highlights key considerations for its responsible implementation, emphasizing standardization, reproducibility, multi-institutional validation, and human oversight.
Reference Key
openalex_W7221688926 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Carla Pitarch-Abaigar, Philipp Lohmann, Patrick Aloy, Fátima Al‐Shahrour, Omar Arnaout, Wenya Linda Bi, Norbert Galldiks, Jason T. Huse, Philipp Karschnia, MacLean P. Nasrallah, Areeba Patel, Rifaquat Rahman, Felix Sahm, Timothy R Smith, Joerg-Christian Tonn, Renato Umeton, Manuel Valiente, Mark Zarella, Raymond Y. Huang, Spyridon Bakas
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag257
URL
https://doi.org/10.1093/neuonc/noag257
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.